UY33164A - Metodo de tratamiento - Google Patents

Metodo de tratamiento

Info

Publication number
UY33164A
UY33164A UY0001033164A UY33164A UY33164A UY 33164 A UY33164 A UY 33164A UY 0001033164 A UY0001033164 A UY 0001033164A UY 33164 A UY33164 A UY 33164A UY 33164 A UY33164 A UY 33164A
Authority
UY
Uruguay
Prior art keywords
treatment method
treatment
hydrates
administration
patient
Prior art date
Application number
UY0001033164A
Other languages
English (en)
Inventor
Valeriu Damian-Iordache
King Andrew
Megan M Mclaughlin
Andrew B Suttle
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of UY33164A publication Critical patent/UY33164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de trastornos de angiogénesis ocular o filtración vascular en un paciente, mediante la administración de inhibidores adecuados, incluyendo pazopanib o sales farmacéuticamente aceptables o hidratos del mismo.
UY0001033164A 2010-01-06 2011-01-04 Metodo de tratamiento UY33164A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06

Publications (1)

Publication Number Publication Date
UY33164A true UY33164A (es) 2011-08-31

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033164A UY33164A (es) 2010-01-06 2011-01-04 Metodo de tratamiento

Country Status (21)

Country Link
US (1) US20130012531A1 (es)
EP (1) EP2521550A4 (es)
JP (1) JP2013516472A (es)
KR (1) KR20120125244A (es)
CN (1) CN102781450A (es)
AU (1) AU2011203706A1 (es)
BR (1) BR112012016673A2 (es)
CA (1) CA2786328A1 (es)
CL (1) CL2012001852A1 (es)
CO (1) CO6561789A2 (es)
DO (1) DOP2012000174A (es)
EA (1) EA201290603A1 (es)
IL (1) IL220594A0 (es)
MA (1) MA33991B1 (es)
MX (1) MX2012007875A (es)
PE (1) PE20121523A1 (es)
PH (1) PH12012501358A1 (es)
SG (1) SG181826A1 (es)
TW (1) TW201201808A (es)
UY (1) UY33164A (es)
WO (1) WO2011085007A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
KR20260025887A (ko) * 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
WO2020261158A1 (en) 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116452A (pt) * 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
EA016227B1 (ru) * 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Способ лечения офтальмологических неоваскулярных расстройств
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
AU2010273254A1 (en) * 2009-07-16 2012-02-02 Glaxo Wellcome Manufacturing Pte Ltd Treatment method

Also Published As

Publication number Publication date
CN102781450A (zh) 2012-11-14
TW201201808A (en) 2012-01-16
AU2011203706A1 (en) 2012-07-12
EA201290603A1 (ru) 2013-03-29
CL2012001852A1 (es) 2012-11-30
PE20121523A1 (es) 2012-12-12
KR20120125244A (ko) 2012-11-14
JP2013516472A (ja) 2013-05-13
EP2521550A1 (en) 2012-11-14
MX2012007875A (es) 2012-08-03
PH12012501358A1 (en) 2019-03-22
CO6561789A2 (es) 2012-11-15
IL220594A0 (en) 2012-08-30
WO2011085007A1 (en) 2011-07-14
EP2521550A4 (en) 2013-07-03
MA33991B1 (fr) 2013-02-01
BR112012016673A2 (pt) 2018-06-05
CA2786328A1 (en) 2011-07-14
DOP2012000174A (es) 2012-12-15
US20130012531A1 (en) 2013-01-10
SG181826A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
CO6561789A2 (es) Método de tratamiento
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
IN2014DN09434A (es)
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201190337A1 (ru) Способ лечения

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191121